Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan Response

被引：0

作者：

Haller, Sven ^{[1
,2
,3
,4
]}

Barkhof, Frederik ^{[5
,6
,7
]}

Thomas, David

Lovblad, Karl-Olof ^{[9
]}

Golay, Xavier ^{[8
]}

Zaharchuk, Greg ^{[10
]}

机构：

[1] Affidea Ctr Diagnost Radiologique Carouge CDRC, Geneva, Switzerland

[2] Uppsala Univ, Div Radiol, Dept Surg Sci, Uppsala, Sweden

[3] Univ Geneva, Fac Med, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland

[4] Univ Hosp Freiburg, Dept Neuroradiol, Freiburg, Germany

[5] UCL, Neuroradiol Acad Unit, Dept Brain Repair & Rehabil, Inst Neurol, London, England

[6] UCL, Dept Healthcare Engn, London, England

[7] Vrije Univ Amsterdam, Med Ctr, Dept Radiol & Nucl Med, Amsterdam, Netherlands

[8] Univ Coll Hosp, UCL Inst Neurol, London, England

[9] Univ Hosp Geneva, Dept Neuroradiol, Geneva, Switzerland

[10] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA

来源：

RADIOLOGY | 2017年 / 284卷 / 01期

关键词：

CEREBROVASCULAR RESERVE; DIFFUSION; RISK;

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

引用

页码：302 / 303

页数：2

共 50 条

[1] Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan
Mugikura, Shunji
Fujimura, Miki
Takahashi, Shoki
Takase, Kei
RADIOLOGY, 2017, 284 (01) : 301 - 302
[2] Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan
Mugikura, Shunji
Fujimura, Miki
Takahashi, Shoki
RADIOLOGY, 2016, 279 (02) : 652 - 653
[3] Evaluating off-label uses of acetazolamide
Van Berkel, Megan A.
Elefritz, Jessica L.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (08) : 524 - 531
[4] Off-label use of ketorolac - Response
Reuben, SS
Connelly, NR
ANESTHESIA AND ANALGESIA, 1996, 83 (01): : 197 - 197
[5] Off-label use of bevacizumab in the treatment of retinal disease: ethical implications
Rohowetz, Landon James
JOURNAL OF MEDICAL ETHICS, 2019, 45 (10) : 668 - 672
[6] Off-label use of antipsychotics: Rethinking "off-label"
Groleger, Urban
PSYCHIATRIA DANUBINA, 2007, 19 (04) : 350 - 353
[7] Off-label use of biologicals in the management of inflammatory oral mucosal disease
O'Neill, Iain David
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2008, 37 (10) : 575 - 581
[8] DupilumabNo therapeutic response and off-label use
Reactions Weekly, 2024, 2011 (1) : 167 - 167
[9] Multiple drugsVarious toxicities, off-label use and no response to off-label therapy: case report
Reactions Weekly, 2021, 1861 (1) : 232 - 232
[10] Acetazolamide/fampridineLack of efficacy and dizziness following off-label use: case report
Reactions Weekly, 2022, 1897 (1) : 16 - 16

← 1 2 3 4 5 →